RGX-202 is a potential one-time AAV Therapeutic for the treatment of Duchenne and includes an optimized transgene for a novel microdystrophin and REGENXBIO's proprietary NAV® AAV8 vector
Commercial-scale cGMP material from the REGENXBIO Manufacturing Innovation Center to be used in the clinical trial
AFFINITY DUCHENNE™ Phase I/II trial of RGX-202 is active and recruiting patients; anticipated to report initial trial data in the second half of 2023
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.